In accordance with an replace from the Meals and Drug Administration (FDA), the labeling for Xeloda (capecitabine) and fluorouracil (5-FU) chemotherapy therapy has been modified to emphasise the dangers related to dihydropyrimidine dehydrogenase (DPD) deficiency; this may have an effect on sufferers receiving the chemotherapy therapy for his or her most cancers.
Sufferers with partial or full DPD deficiency are at elevated threat for extreme, doubtlessly deadly toxicities, together with mucositis, diarrhea, neutropenia and neurotoxicity. The company advises oncologists and different healthcare suppliers to tell sufferers of those dangers and take into account genetic testing earlier than initiating therapy.
Glossary
Dihydropyrimidine dehydrogenase (DPD): an enzyme that breaks down fluoropyrimidines, similar to 5-FU and Xeloda.
Mucositis: an irritation of the mucous membranes.
Neurotoxicity: the harm or dysfunction of the nervous system brought on by publicity to poisonous substances, similar to chemotherapy.
Neutropenia: a situation in which there’s an abnormally low variety of neutrophils, a kind of white blood cell, within the bloodstream.
In an interview with CURE®, Dr. Gabriel A. Brooks mentioned the current FDA product labeling replace for Xeloda and 5-FU which particularly goals to convey consciousness to the dangers related to DPD deficiency and expanded on what he would love sufferers to find out about DPD deficiency.
Brooks presently serves as an affiliate professor of drugs and an affiliate professor of The Dartmouth Institute, Dartmouth Most cancers Middle, The Dartmouth Institute for Well being Coverage and Medical Follow. He’s additionally a member of the Most cancers Inhabitants Sciences Analysis Program, and a member of the Gastrointestinal Medical Oncology Group, at Dartmouth Geisel College of Medication, in Lebanon, New Hampshire.
Transcript:
The primary takeaway message can be to encourage sufferers to ask their docs about DPD deficiency, and to ask sufferers to open up a dialog with their docs about getting examined for DPD deficiency earlier than beginning 5-FU and [Xeloda].
Proper now, the FDA recommends that docs talk about DPD deficiency with their sufferers, however we all know that many docs aren’t doing that. The rules on the market have been just a little blended. In Europe, it’s customary of care to supply this take a look at earlier than beginning chemotherapy. In lots of facilities in america, that is turning into customary of care earlier than beginning 5-FU and [Xeloda] chemotherapy; nonetheless, in different facilities, this take a look at is just not uniformly used. I’m a believer that it needs to be used earlier than therapy, and I encourage sufferers to debate it with their docs, as suggested on the FDA drug labels for 5-FU and [Xeloda].
This take a look at is just not uniformly used, so it is value bringing this up for dialogue along with your physician and understanding that your physician is probably not planning to order this take a look at until you convey it up for dialogue with them.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
